Last updated on August 2018

The Benefit/Risk Profile of AOP2014 in Low-risk Patients With PV


Brief description of study

The Low-PV study is a multicenter, phase II, randomized trial aimed to assess whether the addition of Pegylated Proline-interferon-alpha-2b to the best therapeutic current strategy available based on phlebotomies and low dose acetylsalicylic acid (ASA) could improve the efficacy of treatment of patients with PV at low risk of thrombosis (younger than 60 years and without prior vascular events), in term of control of recommended level of hematocrit < 45%, over a period of 12 months.

Detailed Study Description

It is an independent, investigator-generated, pragmatic trial including adult PV patients (aged 18-60) diagnosed according to World Health Organization 2008 criteria within the last 3 years before inclusion, without history of thrombosis and younger than 60 years ('low risk' patients).

Eligible patients are randomized to be treated with the best available therapy (recommended for this risk class, standard arm) based on phlebotomy including administration of low-dose (100 mg/daily) of acetylsalicylic acid (ASA, when there are not contraindications) OR Pegylated Proline-Interferon alpha-2b (AOP2014) every 2 weeks in addition to the recommended available regimen (experimental arm), for up to 12 months. The allocation of patients to study arms is 1:1 and stratification at randomization will be performed according to age category (< 50 years old or > 50 years old) and time from diagnosis (nave or non-nave). Naive patients are defined as new cases coming to observation, diagnosed for the first time just before study entry and never treated; non-naive patients are old cases (diagnosis not older than 3 years before study entry) undergoing therapy with phlebotomy and/or low doses of ASA.

Primary endpoint (PEp) is defined by the proportion (%) of patients who maintain the median value of hematocrit (HCT) below 45% during 12 months of treatment in each arm, without progression of disease and no need of any extra-protocol cytoreductive drug (responder patients).

Secondary endpoints include evaluation of hematological and molecular response, histological remission and safety profile of the protocol therapy.

Before randomization all patients undergo phlebotomies in order to reach an HCT below 45%.

After randomization, according to current common clinical practice the regimen of phlebotomies must be selected accordingly to maintain the recommended level of HCT< 45%. Once normalization of the HCT has been achieved, blood counts at regular intervals (every 4 weeks) will establish the frequency of future phlebotomies. Sufficient blood is recommended to be removed in order maintain the hematocrit below 45%. Supplemental iron therapy should not be administered.

All patients receive low-dose of ASA (100 mg/daily) as recommended by the current guidelines for low-risk subjects with PV.

Patients allocated in the experimental group receive in addition a pre-filled auto-injection pen for the subcutaneous auto-administration (into the abdominal skin or the thigh) of 100 g of Pegylated Proline-Interferon alpha-2b (AOP2014) once every 14 days.

Patient visits are scheduled every month (4 weeks) for 12 months to assess and perform a reliable calculation of the primary end-point (% of patients with median HCT levels <45%).

At each monthly visit a pre-filled auto-injection pen is delivered to the patients who have been randomized in the experimental arm.

Assuming an expected drop-out rate of 12%, a total sample size of 150 patients (75 randomized in each group) will be randomized to reject the null hypothesis that the proportion of patients achieving the primary endpoint is 50% in favor of the alternative hypothesis that this proportion is 75% when AOP2014 is added to the phlebotomy based- therapy, with a power of 80% and an alpha error of 0.05 (two-tailed).

The primary endpoint assessment is performed after the completion of the first 12 months of therapy for all subjects enrolled ('core study').

A period of 12 months is expected for completion of the enrolment / randomization phase. The 'core study' itself will take 12 months of treatment per patient.

Based on results from the 'core study' the extension phase will continue as follows:

  1. After 12 month patients who meet the primary endpoint following either conventional or experimental therapy will enter the extension phase and remain on their current regimen.
  2. non-responders, not meeting the primary endpoint after 12 months of conventional therapy will be switched to the experimental treatment.
  3. non-responder, not meeting the primary endpoint after 12 months of experimental therapy will be switched to conventional treatment.

This extension phase will last for another 12 months from the Last Visit Last Patient included (LVLP) into the core study (matching cases 1 and 2 as defined above). Based on this, the overall length of the study is expected to cover a period of 36 months from the First Patient Included (FPI).

Clinical Study Identifier: NCT03003325

Contact Investigators or Research Sites near you

Start Over

Nicola Cascavilla, MD

U.O. Ematologia, Ospedale Casa Sollievo della Sofferenza Istituto di Ricovero e Cura a Carattere Scientifico
San Giovanni Rotondo, Italy
  Connect »

Fabrizio Pane, MD

Azienda Ospedaliera Universitaria Federico II di Napoli
Napoli, Italy
  Connect »

Michele Cavo, MD

Divisione Ematologia Policlinico S. Orsola - Malpighi
Bologna, Italy
  Connect »

Arianna Masciulli, PharmD

Clinica Ematologica, Azienda Ospedaliero-Universitaria "Santa Maria della Misericordia"
Udine, Italy
  Connect »

Valerio De Stefano, MD

UCSC Ematologia, Fondazione Policlinico Universitario "Agostino Gemelli"Universit Cattolica del Sacro Cuore
Roma, Italy
  Connect »

Alessandra Iurlo, MD

Divisione Oncoematologia, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico
Milano, Italy
  Connect »

Arianna Masciulli, PharmD

Divisione Ematologia ASST, Grande Ospedale Metropolitano Niguarda
Milano, Italy
  Connect »

Arianna Masciulli, PharmD

Divisione Ematologia, ASST di MONZA - Ospedale San Gerardo di Monza
Monza, Italy
  Connect »

Elisa Rumi, MD

Divisione Ematologia, Fondazione IRCCS Policlinico San Matteo
Pavia, Italy
  Connect »

Francesco Passamonti, MD

U.O. Ematologia, Ospedale di Circolo e Fondazione Macchi Varese
Varese, Italy
  Connect »

Davide Rapezzi, MD

S.C. Ematologia Azienda Ospedaliera S. Croce e Carle Cuneo
Cuneo, Italy
  Connect »

Arianna Masciulli, PharmD

SCDU Ematologia, A.O.U. Maggiore della Carit
Novara, Italy
  Connect »

Umberto Vitolo, MD

S.C. Ematologia, AOU- Presidio Ospedaliero Molinette
Torino, Italy
  Connect »

Giorgina Specchia, MD

U.O. Ematologia con Trapianto, Azienda Universitaria Ospedaliera Consorziale - Policlinico Bari
Bari, Italy
  Connect »

Arianna Masciulli, PharmD

Unit Operativa Complessa di Emostasi Azienda Ospedaliero-Universitario "Policlinico Vittorio-Emanuele - Presidio Ospedaliero Ferrarotto
Catania, Italy
  Connect »

Caterina Musolino, MD

UOC Ematologia, Azienda Ospedaliera Universitaria Policlinico "G. Martino"
Messina, Italy
  Connect »

Sergio Siragusa, MD

Divisione Ematologia Azienda Ospedaliera Universitaria Policlinico "Paolo Giaccone" Palermo
Palermo, Italy
  Connect »

Alessandro Vannucchi, MD

SOD Ematologia AUOC Azienda Ospedaliero-Universitaria "Careggi"
Firenze, Italy
  Connect »

Arianna Masciulli, PharmD

Clinica Medica I Azienda Ospedaliera di Padova
Padova, Italy
  Connect »

Massimiliano Bonifacio, MD

Divisione Ematologia, Ospedale Borgo Roma
Verona, Italy
  Connect »

Marco Ruggeri, MD

Divisione Ematologia, Ospedale San Bortolo
Vicenza, Italy
  Connect »

Alessandro Rambaldi, MD

UOC Ematologia, ASST Papa Giovanni XXIII
Bergamo, Italy
  Connect »

Fabio Ciceri

IRCCS Ospedale San Raffaele
Milano, Italy
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.